Overview

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Status:
Completed
Trial end date:
2020-07-29
Target enrollment:
Participant gender:
Summary
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could have failed up to three prophylactic treatments out of: propranolol/metoprolol, amitriptyline, flunarizine. Patients were stratified into groups according to their number of migraine days during the baseline period.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Erenumab
Topiramate